9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis

Cancer

Volumn 114, Issue 3, 2008, Pages 204-215

  Onofre, Fabiana Botelho De Miranda ^a   Onofre, Alexandre Sherlley Casimiro ^a   Pomjanski, Natalia ^a   Buckstegge, Birgit ^a   Grote, Hans Juergen ^a,b   Böcking, Alfred ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

9p21; AgNOR analysis; CDKN2A; DNA ICM; Effusion; Fluorescence in situ hybridization; Immunocytochemistry; Mesothelioma

Indexed keywords

CALRETININ; EPITHELIAL MEMBRANE ANTIGEN; GLYCOPROTEIN; MESOTHELIN; WT1 PROTEIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME NOR; CLINICAL ARTICLE; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; DNA IMAGE CYTOMETRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; SILVER STAINING;

AGED; AGED, 80 AND OVER; ANEUPLOIDY; ANTIGENS, NUCLEAR; ASCITIC FLUID; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; DNA; FEMALE; HUMANS; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS;

EID: 47049096400     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23413     Document Type: Article

References (53)

1. Churg A, Cagle PT, Roggli VL.Tumors of the serosal membranes. In: Atlas of Tumor Pathology. 4th series, fascicle 10. Washington, DC: Armed Forces Institute of Pathology; 2006.
2. Yarborough CM. The risk of mesothelioma from exposure to chrysotile asbestos. Curr Opin Pulm Med. 2007;13:334-338.
3. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006;23:56-60.
4. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.
5. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260-271.
6. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92:587-593.
7. Price B, Ware A. Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004;159:107-112.
8. Leigh J, Davidson P, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med. 2002; 41:188-201.
9. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-672.
10. Gray W, Mckee GT. Diagnostic Cytopathology. 2nd ed. Edinburgh: Churchill Livingstone; 2003.
11. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol. 1998;19:131-137.
12. Illei PB, Ladanyi M, Rusch VW, Zakowski M. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer (Cancer Cytopathol). 2003;99:51-56.
13. Haroske G, Baak JP, Danielsen H, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol. 2001;23:89-95.
14. Böcking A.DNA measurements. When and why? In: Wied GL,Keebler CM, Rosenthal DL, Schenk U, Somrak TM, Vooijs GP, eds. Compendium on Quality Assurance, Proficiency Testing, and Workload Limitations. Chicago: Tutorials of Cytology; 1995:170-188.
15. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of the epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38: 1-16.
16. Derenzini M. The AgNORs. Micron. 2000;31:117-120.
17. Sirri V; Roussel P; Hernandez-Verdun D. The AgNOR proteins: qualitative and quantitative changes during the cell cycle. Micron. 2000;31:121-126.
18. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet. 2001;127:93-110.
19. Illei PB; Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9:2108-2113.
20. INK4 locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23:1127-1130.
21. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer. 1997;75:523-527.
22. Xiao S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesomelioma. Oncogene. 1995;11:511-515.
23. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54:5547-5551.
24. Stahel RA. Malignant pleural mesothelioma: a new standard of care. Lung Cancer. 2006;545:S9-S14.
25. Koss LG, Melamed MR.Koss' diagnostic cytology and its histopathologic bases. Volumes I and II. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
26. Chatelain R, Willms A, Biesterfeld S, Auffermann W, Bocking A. Automated Feulgen staining with a temperature controlled staining machine. Anal Quant Cytol Histol. 1989;11: 211-217.
27. Haroske G, Giroud F, Reith A, Böcking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Anal Cell Pathol. 1998;17: 189-200.
28. Giroud F, Haroske G, Reith A, Böcking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations for quality assurance. European Society for Analytical Cellular Pathology. Anal Cell Pathol. 1998;17:201-207.
29. Böcking A, Giroud F, Reith A. Consensus report of the ESACP task force on standardization of diagnostic DNA image cytometry. European Society for Analytical Cellular Pathology. Anal Cell Pathol. 1995;8:67-74.
30. Biesterfeld S, Gerres K, Fischer-Wein G, Böcking A. Polyploidy in non-neoplastic tissues. J Clin Pathol. 1994;47:38-42.
31. Motherby H, Kube M, Friedrichs N, et al. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology. I. Prevalence of markers in tumor cell positive and negative smears. Anal Cell Pathol. 1999;19:7-20.
32. Motherby H, Marcy T, Hecker M, et al. Static DNA cytometry as a diagnostic aid in effusion cytology. I. DNA aneuploidy for identification and differentiation of primary and secondary tumor of the serous membranes. Analyt Quant Cytol Histol. 1998;20:1-9.
33. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ. Improvement in me staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J. 1986;18:5-14.
34. Crocker J, Boldy DA, Egan MJ. How should we count AgNORs? Proposals for a standardized approach. J Pathol. 1989;158:185-188.
35. Rüschoff J. Nukleolus Organisierende Regionen (NORs) in der Pathomorphologischen Tumordiagnostik. Stuttgart: Gustav Fischer Verlag; 1992.
36. Pomjanski N, Motherby H, Buckstegge B, Knops K, Rohn BL, Böcking A. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis. Analyt Quant Cytol Histol. 2001;23:151-160.
37. Osterheld MC, Liette C, Anca M. Image Cytometry: an aid for cytological diagnosis of pleural effusions. Diagn Cytopathol. 2005;32:173-176.
38. Motherby H, Pomjanski N, Kube M, et al. Diagnostic DNA-flow vs. image-cytometry in effusion cytology. Anal Cell Pathol. 2002;24:5-15.
39. Kayser K, Blum S, Beyer M, Haroske G, Kunze KD, Meyer W. Routine DNA cytometry of benign and malignant pleural effusions by means of the remote quantification server Euroquant: a prospective study. J Clin Pathol. 2000;53:760-764.
40. Palaoro LA, Blanco AM, Gamboni M, Rocher AE, Rotenberg RG. Usefulness of ploidy, AgNOR and immunocytochemistry for differentiating benign and malignant cells in serous effusions. Cytopathology. 2007;18:33-39.
41. Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15-19.
42. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34-48.
43. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
44. Comin AE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, Thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529-535.
45. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagnostic Cytopathol. 2005;32:151-155.
46. Ordonez NG. Value of thyroid transcription factor-1, E-Cadherin, BG8, WT1, and CD44s immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
47. Wolanski KD, Whitaker D, Shilkin KB, Henderson DW. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590.
48. Mohanty SK, Dey P, Rana P. Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions. Anal Quant Cytol Histol. 2003;25:273-276.
49. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006;170:9-15.
50. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma Int J Cancer. 1998;75:649-653.
51. Zellweger T, Benz G, Cathomas G, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006;119: 1660-1665.
52. Metzgeroth G, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology. 2007;DOI: 10.1111/j.1365-2303.2007.00468.x. In press.
53. Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Böcking A. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol. 2005;33:309-315.